参考文献/References:
[1]Lee J,Vasikaran S.Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis[J].Ann Lab Med,2012,32(2):105-112.[2]Montalcini T,Gallotti P,Coppola A,et al.Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes[J].Osteoporos Int,2015,26(5):1639-1646.[3]Richter B,Faul C.FGF23 Actions on Target Tissues-With and Without Klotho[J].Front Endocrinol (Lausanne),2018,9:189.[4]Hu MC,Shi M,Zhang J,et al.Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule[J].FASEB J,2010,24(9):3438-3450.[5]Galliera E,Marazzi MG,Gazzaruso C,et al.Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study[J].Immun Ageing,2017,14:13.[6]Silver J,Naveh-Many T.FGF23 and the parathyroid[J].Advances in experimental medicine and biology,2012,728:92-99.[7]Eller-Vainicher C,Cairoli E,Grassi G,et al.Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility[J].J Diabetes Res,2020,2020:7608964.[8]Compston J.Type 2 diabetes mellitus and bone[J].J Intern Med,2018,283(2):140-153.[9]Siddappa R,Mulder W,Steeghs I,et al.cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models[J].Tissue Eng Part A,2009,15(8):2135-2143.[10]周相娟,郑立强,金秀平.106例2型糖尿病患者骨密度变化的临床观察[J].重庆医学,2009,38(21):2717-2718.[11]Wolf M.Forging forward with 10 burning questions on FGF23 in kidney disease[J].J Am Soc Nephrol，2010，21(9):1427-1435.[12]Seiler S,Heine GH,Fliser D.Clinical relevance of FGF-23 in chronic kidney disease[J].Kidney Int Suppl，2009(114):S34-S42.[13]Titan SM,Zatz R,Graciolli FG,et al.FGF-23 as a predictor of renal outcome in diabetic nephropathy[J].Clin J Am Soc Nephrol,2011,6(2):241-247.[14]Galliera E,Marazzi MG,Gazzaruso C,et al.Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study[J].Immun Ageing,2017,14:13.[15]Perico N,Remuzzi G,Benigni A.Aging and the Kidney[J].Current Opinionin Nephrology and Hypertension,2011,20:312.[16]Zanchi C,Locatelli M,Benigni A,et al.Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor[J].PLoS One,2013,8(8):e70775.[17]Kuro-o M.Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism[J].Curr Opin Nephrol Hypertens,2006,15(4):437-441.[18]Nakai K,Komaba H,Fukagawa M.New insights into the role of fibroblast growth factor 23 in chronic kidney disease[J].J Nephrol,2010,23(6):619-625.[19]Inci A,Sari F,Olmaz R,et al.Soluble Klotho levels in diabetic nephropathy: relationship with arterial stiffness[J].Eur Rev Med Pharmacol Sci,2016,20(15):3230-3237.[20]Yamada H,Kuro-O M,Hara K,et al.The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease[J].PLoS One,2016,11(8):e0160782.[21]El-Saeed AM,El-Mohasseb GF.Circulating Fibroblast Growth Factors 21 and 23 as Biomarkers of Progression in Diabetic Nephropathy in Type 2 Diabetes with Normoalbuminuria[J].Egypt J Immunol,2017,24(2):93-99.[22]Chen H,Li J,Zhang D,et al.Role of the fibroblast growth factor 19 in the skeletal system[J].Life Sci,2021,265:118804.[23]Zhang X,Guo K,Xia F,et al.FGF23C-tail improves diabetic nephropathy by attenuating renal fibrosis and inflammation[J].BMC Biotechnol,2018,18(1):33.[24]Wang H,Yoshiko Y,Yamamoto R,et al.Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro[J].J Bone Miner Res,2008,23(6):939-948.[25]Sitara D,Razzaque MS,Hesse M,et al.Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice[J].Matrix Biol,2004,23(7):421-432.[26]Jüppner H.Phosphate and FGF-23[J].Kidney Int,2011,79121:S24-S27.[27]Uhlig K,Berns JS,Kestenbaum B,et al.KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)[J].Am J Kidney Dis,2010,55(5):773-799.[28]Kanda E,Yoshida M,Sasaki S.Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients[J].BMC Nephrol,2012,13:122.[29]Khundmiri SJ,Murray RD,Lederer E.PTH and vitamin D[J].Compr Physiol,2016,6(2):561-601．[30]韩冬梅,毛维维,巩伟伟,等.2型糖尿病肾病患者临床分期与骨质疏松及生长因子的关系[J].医学临床研究,2020,37(9):1297-1299.